Cluster 4/5 was treated with the dual ICI regimen of ipilimumab plus nivolumab. This arm remains open to accrual. Clusters 3, 6, and 7 were excluded from the study. Additional secondary endpoints are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback